Slattery Martha L, Samowitz Wade, Curtin Karen, Ma Khe Ni, Hoffman Michael, Caan Bette, Neuhausen Susan
Health Research Center, School of Medicine, University of Utah, Salt Lake City, 84108, USA.
Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1206-14.
Insulin, insulin-like growth factor (IGF), and IGF binding protein (IGFBP) are involved in cell growth and proliferation and are thought to be important in the etiology of colorectal cancer. We hypothesize that genetic polymorphisms of insulin receptor substrates (IRS-1 and IRS-2), IGF-I, and IGFBP-3 alter colorectal cancer risk because of their roles in the insulin-related signaling pathway.
Data from a population-based incident case-control study of 1,346 colon cancer cases and 1,544 population-based controls and 952 rectal cancer cases and 1,205 controls were used to evaluate associations. Genetic polymorphisms of four genes were investigated: an IGF1 CA repeat, the IGFBP3 -202 A > C, the IRS1 G972R, and the IRS2 G1057D.
Having at least one R allele (GR or RR) for IRS1 G972R was associated with an increased risk of colon cancer [odds ratio 1.4, 95% confidence interval (95% CI) 1.1-1.9]. The IRS2 G972R heterozygote GD genotype significantly reduced risk of colon cancer (odds ratio 0.8, 95% CI 0.6-0.9). Neither the IGF1 nor the IGFBP3 variants was associated independently with colon cancer, but there was an association when examined with IRS1. Individuals with an IRS1 R allele and IGF1 non-192 allele were at a 2-fold increased risk of colon cancer (95% CI 1.2-4.4). There was a 70% (95% CI 1.02-2.8) increased risk of colon cancer with an IRS1 R allele and the IGFBP3 AC or CC genotype. The IRS2 GD genotype reduced risk of colon cancer, except among those with an IRS1 R allele. No significant associations were seen in analyses of main effects or interactions of these variants and rectal cancer risk.
Both IRS1 and IRS2 variants were associated with colon cancer risk independently. Associations were slightly stronger when polymorphisms in multiple genes were evaluated in conjunction with other genes rather than individually. These data suggest that the insulin-related pathway may be important in the etiology of colon cancer but not rectal cancer.
胰岛素、胰岛素样生长因子(IGF)和IGF结合蛋白(IGFBP)参与细胞生长和增殖,被认为在结直肠癌的病因学中起重要作用。我们假设胰岛素受体底物(IRS - 1和IRS - 2)、IGF - I和IGFBP - 3的基因多态性会改变结直肠癌风险,因为它们在胰岛素相关信号通路中发挥作用。
基于人群的1346例结肠癌病例和1544例人群对照以及952例直肠癌病例和1205例对照的发病病例对照研究数据用于评估关联性。研究了四个基因的基因多态性:IGF1 CA重复序列、IGFBP3 - 202 A > C、IRS1 G972R和IRS2 G1057D。
IRS1 G972R至少有一个R等位基因(GR或RR)与结肠癌风险增加相关[比值比1.4,95%置信区间(95%CI)1.1 - 1.9]。IRS2 G972R杂合子GD基因型显著降低结肠癌风险(比值比0.8,95%CI 0.6 - 0.9)。IGF1和IGFBP3变体均未独立与结肠癌相关,但与IRS1一起检测时存在关联。携带IRS1 R等位基因和IGF1非192等位基因的个体患结肠癌的风险增加2倍(95%CI 1.2 - 4.4)。携带IRS1 R等位基因和IGFBP3 AC或CC基因型时,患结肠癌的风险增加70%(95%CI 1.02 - 2.8)。IRS2 GD基因型降低结肠癌风险,但携带IRS1 R等位基因的个体除外。在分析这些变体与直肠癌风险的主效应或相互作用时未发现显著关联。
IRS1和IRS2变体均独立与结肠癌风险相关。当多个基因的多态性与其他基因联合评估而非单独评估时,关联性略强。这些数据表明胰岛素相关通路可能在结肠癌而非直肠癌的病因学中起重要作用。